PROMISING PROGRESS: Improving Knowledge of Emerging Treatments in Advanced Pancreatic Cancer
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: February 01, 2016
Expiration Date: February 01, 2017
Expected time to complete this activity as designed: 90 minutes
There are no fees for participating in or receiving credit for this online activity.
Pancreatic cancer (PC) is associated with the lowest survival rate of any major cancer: not only are there few screening tools that can accurately identify PC in an unselected population, but neither clinical examination nor serological markers are effective for early detection. Pancreatic cancer is also inherently resistant to most available treatments. However, the emerging recognition of the pancreatic cancer microenvironment, including the particularly abundant stroma, is playing a key role in understanding disease progression and resistance to chemotherapy. Today, two new front line therapies are shifting the treatment paradigm for the treatment of advanced metastatic pancreatic cancer. In this activity, faculty will discuss the latest research on the biology of metastatic pancreatic cancer, and how an understanding of this information can support improved individualized therapeutic strategies, both with today’s current treatment landscape and future therapeutic targets.
This activity is designed for community oncologists, pharmacists, and allied health care professionals who may provide care to patients with pancreatic cancer.
Upon completion of this educational activity, participants should be able to:
- Summarize recent advances in frontline therapy, including those emerging options being studied in clinical trials
- Structure a patient-centered treatment plan for patients with advanced pancreatic cancer, factoring performance status, age, comorbidities, and patient considerations into treatment decisions
- Recognize the importance of shared decision-making in caring for patients with pancreatic cancer
- Outline new and emerging data relative to potential for treatment sequencing and options beyond first-line therapy
Promising Progress: Improving Knowledge of Emerging Treatments in Advanced Pancreatic Cancer – James L. Abbruzzese, MD; Andrew H. Ko, MD; Philip A. Philip, MD, PhD
Instructions for Participation and Credit
This activity is eligible for credit through February 01, 2017. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.
James L. Abbruzzese, MD, FACP, FASCO
Professor of Medicine
Chief, Division of Medical Oncology, Department of Medicine
Associate Director for Clinical Research and Training
Duke Cancer Institute
Durham, North Carolina
Dr. James Abbruzzese received his medical degree (with honors) from the University of Chicago, Pritzker School of Medicine. He completed his internship and residencies in internal medicine, as well as a clinical fellowship in infectious diseases at Johns Hopkins Hospital, Baltimore. In addition, he completed clinical fellowships in medical oncology at Dana-Farber Cancer Institute, Harvard Medical School, Boston. Dr. Abbruzzese is currently chief in the Division of Medical Oncology, Department of Medicine, and is associate director for clinical research and training at Duke Cancer Institute.
Dr. Abbruzzese has specialty certification from the American Board of Internal Medicine, and the American Board of Internal Medicine (medical oncology). He holds membership in the National Cancer Institute, American Association for Cancer Research, and American Society of Clinical Oncology. He is deputy editor, Clinical Cancer Research, and on the editorial board of Investigational New Drugs, Cancer Prevention Research, and Cancer Research. Dr. Abbruzzese’s areas of research interest include pancreatic, colorectal, and hepatobiliary cancer biology and therapy; targeted therapeutics; and predictive and prognostic biomarkers, and he has published hundreds of journals, articles, books, book chapters, and abstracts on these topics.
Andrew H. Ko, MD
Associate Professor of Clinical Medicine
Department of Medicine
Division of Hematology/Oncology
University of California, San Francisco
San Francisco, California
Dr. Andrew Ko received his medical degree from Johns Hopkins School of Medicine. He completed his internship and residency in internal medicine at Beth Israel Hospital/Harvard Medical School and his fellowship in medical oncology at Stanford University School of Medicine. He is currently associate professor of clinical medicine, Department of Medicine at the University of California, San Francisco (UCSF).
Dr. Ko is board certified in internal medicine and medical oncology. He is on the Board of Directors of the Association of Northern California Oncologists and holds memberships in the Massachusetts Medical Society, American Society of Clinical Oncology (ASCO), American Association for Cancer Research, Cancer and Leukemia Group B (CALGB), Pancreatic Cancer Task Force/National Cancer Institute (NCI), and National Comprehensive Cancer Network (NCCN)/Pancreatic Adenocarcinoma Panel. In addition, Dr. Ko is an ad hoc referee for Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, The New England Journal of Medicine, Lancet Oncology, Investigational New Drugs, Molecular Cancer Therapeutics, British Journal of Cancer, Expert Opinion on Pharmacotherapy, Journal of Molecular Medicine, American Journal of Cancer, and World Journal of Surgical Oncology, and is on the editorial board of People Living With Cancer (ASCO),The Oncologist, HemOnc Today, and the Journal of Clinical Oncology. Dr. Ko’s areas of interest include gastrointestinal malignancies (pancreatic cancer, colorectal cancer, esophageal cancer, gastric cancer, hepatocellular cancer, anal cancer, neuroendocrine tumors), clinical trials, molecular predictors, biologic therapy, targeted therapy, investigational new agents, and circulating tumor cells.
Philip A. Philip, MD, PhD, FRCP
Professor of Oncology and Internal Medicine
Dr. Kathryn Cramer Endowed Chair in Cancer Research
Leader, GI & Neuroendocrine Multidisciplinary Team
Vice President for Medical Affairs
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine
Dr. Philip Philip received his medical degree from the University of Baghdad, College of Medicine in Iraq, and his PhD in clinical pharmacology and pharmacogenetics at the University of London Guy’s Hospital Medical School in the UK. He completed a residency at the University of Baghdad, and a fellowship in medical oncology at the University of Oxford and the MD Anderson Cancer Center in Houston, Texas. Dr. Philip is a professor of oncology and medicine at the Wayne State University School of Medicine and the Karmanos Cancer Center. He is the leader of the GI & neuroendocrine multidisciplinary team and vice president for medical affairs at the Karmanos Cancer Institute, as well as the Kathryn Cramer MD Endowed Professor in Cancer Research at Wayne State University School of Medicine in Detroit
Dr. Philip is USA board-certified in medical oncology and a fellow of the Royal College of Physicians in the UK. He chairs the pancreatic cancer committee at the Southwest Oncology Group (SWOG) and is a member of the International Liver Cancer Association and the American Society of Clinical Oncology.
A frequent national and international lecturer, Dr. Philip authored over 200 manuscripts, review articles, editorials, and co-edited a book on pancreatic cancer. His major research interests are in the development of new therapies for gastrointestinal and neuroendocrine cancers with a special focus on pancreatic cancer. He has been the principal investigator on numerous local and national clinical trials in GI cancers.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.5 contact hours. Program Number: 16-062-025
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Dr. James Abbruzzese has received honoraria related to formal advisory activities from Celgene Corporation, EMD Serono, Inc., and Halozyme, Inc., as well as consultant fees from Celgene and Halozyme.
Dr. Andrew Ko has received honoraria related to formal advisory activities from EMD Serono, Inc., Halozyme, Inc., Incyte Corporation, and Merrimack Pharmaceuticals, Inc. He has received grant support related to research activities from Acerta Pharma, Aduro Biotech, Merrimack, and PRISM BioLab Co., Ltd.
Dr. Philip Philip has received consultant fees from Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Clovis Oncology, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genomic Health, Inc., Gilead, Halozyme, Inc., Novartis AG, Onyx, and sanofi-aventis U.S. LLC.; honoraria related to formal advisory activities from Boehringer Ingelheim, Celgene, Gilead, MedImmune, LLC, Merrimack Pharmaceuticals, Inc., Novartis; as well as speakers’ bureau activities from Amgen, Bayer, Celgene, Eli Lilly, F. Hoffmann-La Roche, Genentech, Inc., Novartis, Onyx, and Sanofi. He has received grant support related to research activities from Abbott, Bayer, Bristol-Myers Squibb, Celgene, Eli Lilly, F. Hoffmann-La Roche, Incyte, Nektar, Novartis.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Off-Label Disclosures/Investigational Disclosures
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.
Dr. Abbruzzese has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Abbruzzese has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Dr. Ko has indicated that he does not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Ko has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
Dr. Philip has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.
Dr. Philip has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.